Algernon Pharmaceuticals Announces Positive Trending Interim Data for its Phase 2b/3 Ifenprodil COVID Study
Company or
Algernon ) a clinical stage pharmaceutical development company, is pleased to report, in a descriptive format, positive trending interim data for the Phase 2b part of the Company s Phase 2b/3 clinical study of Ifenprodil for COVID-19.
For the endpoint of ventilation by day 15, there was a trend towards fewer patients requiring mechanical ventilation in the high dose Ifenprodil treatment arm, as compared to patients who were in the untreated arm of the study. Mechanical ventilation is associated with poor prognosis in COVID-19 patients, including increased risk of mortality and procedural complications.
Share this article
Share this article
ResearchAndMarkets.com s offering.
This report delivers an in-depth understanding of the Acute Respiratory Distress Syndrome (ARDS), historical and forecasted epidemiology as well as the Acute Respiratory Distress Syndrome (ARDS) market trends in the United States, EU5 (Germany, France, Italy, and United Kingdom) and Japan.
The Acute Respiratory Distress Syndrome (ARDS) market report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted 7MM Acute Respiratory Distress Syndrome (ARDS) market size from 2017 to 2030. The report also covers current Acute Respiratory Distress Syndrome (ARDS) treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
IIROC Trading Halt investingnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investingnews.com Daily Mail and Mail on Sunday newspapers.
Dec 11, 2020
Malin Dunfors, Market One Media Algernon Pharmaceuticals has been hard at work repurposing Ifenprodil for those affected by idiopathic pulmonary fibrosis, chronic cough, as well as COVID-19. , Market One Media
New England Journal of Medicine reports that four repurposed antiviral drugs tested in 11,330 patients hospitalized with COVID-19 showed little to no effect
Decemberâs release of interim data from the companyâs Ifenprodil COVID-19 multinational trial marks important milestone
The IPF (Idiopathic Pulmonary Fibrosis) market is expected to grow to USD$3.6 billion by 2029
In mid-January, scientists published the genetic sequence of the coronavirus, thought to be behind the outbreak of a new form of pneumonia. Not long after, the hunt for a potential coronavirus vaccine began.